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Abstract: Akkermansia muciniphila and Faecalibacterium prausnitzii are highly abundant human gut
microbes in healthy individuals, and reduced levels are associated with inflammation and alterations
of metabolic processes involved in the development of type 2 diabetes. Dietary factors can influence the
abundance of A. muciniphila and F. prausnitzii, but the evidence is not clear. We systematically searched
PubMed and Embase to identify clinical trials investigating any dietary intervention in relation to
A. muciniphila and F. prausnitzii. Overall, 29 unique trials were included, of which five examined
A. muciniphila, 19 examined F. prausnitzii, and six examined both, in a total of 1444 participants.
A caloric restriction diet and supplementation with pomegranate extract, resveratrol, polydextrose,
yeast fermentate, sodium butyrate, and inulin increased the abundance of A. muciniphila, while a
diet low in fermentable oligosaccharides, disaccharides, monosaccharides, and polyols decreased
the abundance of A. muciniphila. For F. prausnitzii, the main studied intervention was prebiotics
(e.g. fructo-oligosaccharides, inulin type fructans, raffinose); seven studies reported an increase after
prebiotic intervention, while two studies reported a decrease, and four studies reported no difference.
Current evidence suggests that some dietary factors may influence the abundance of A. muciniphila
and F. prausnitzii. However, more research is needed to support these microflora strains as targets of
microbiome shifts with dietary intervention and their use as medical nutrition therapy in prevention
and management of chronic disease.
Keywords: Akkermansia muciniphila; Faecalibacterium prausnitzii; microbiome; systematic review;
randomized controlled trials; dietary interventions
1. Introduction
The gut microbiota, defined as the complex, diverse, and vast microbial community resided in
the human gut, is emerging as a key player in the pathophysiology of several chronic conditions [1].
Gut microbiota extract energy from nutrients and regulate several biological processes. A microbiota
imbalance, such as low abundance of Akkermansia muciniphila and Faecalibacterium prausnitzii, favours
inflammatory processes, potentially leading to inflammatory disorders of the gastrointestinal tract
such as irritable bowel syndrome and inflammatory bowel disease, as well as to colorectal cancer [2–6].
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Also, increases in A. muciniphila and F. prausnitzii abundance can regulate metabolic functions and
appear to exert protective effects against the development of obesity [7], type 2 diabetes (T2D) [8],
and atherosclerosis [9]. Therefore, these two bacteria have been considered as potential bioindicators
of human cardiometabolic health and conditions where underlying inflammation plays a role.
A. muciniphila is a mucin-degrading bacterium of the phylum Verrucomicrobia, while F. prausnitzii is an
important butyrate-producer of the phylum of Firmicutes. F. prausnitzii is also the major bacterium of
the Clostridium leptum group [10,11]. It accounts for 5% of total bacteria in faeces and it is an important
source of energy for the colonocytes [12,13].
Modulating the abundance of A. muciniphila and F. prausnitzii in the intestinal flora may contribute to
prevent and treat inflammatory and cardiometabolic diseases [14–16]. Studies have shown that dietary
factors can influence the diversity and composition of the gut microbiome more than human genetic
factors [17]. Data from animal studies suggest that polyphenols-rich diets and specific phytochemicals
such as curcumin and epigallocatechin gallate may improve the abundance of A. muciniphila and
F. prausnitzii in the gut microbiome [18–22]. A clinical trial with obese insulin-resistant patients showed
that resveratrol, a natural phenol, increased the abundance of A. muciniphila in Caucasians but not in
other ethnic groups [23]. A diet high in fermentable oligo-, di- and monosaccharides and polyphenols
(FODMAP), which has been implicated in digestive diseases such as irritable bowel syndrome,
inflammatory bowel disease, and Crohn’s disease, resulted in changes in gut microbiota including
changes in A. muciniphila and F. prausnitzii but the evidence is not consistent [24,25]. Furthermore,
intake of dietary fibres, such as the soluble fibre inulin, has been associated with increased abundance
of A. muciniphila and F. prausnitzii in healthy and overweight/obese individuals, but another study
showed no influence of inulin intake on F. prausnitzii [26–28]. Despite the emerging evidence of the
impact of dietary factors on changing the microbiome composition, a comprehensive assessment of
the dietary interventions in modulating A. muciniphila and F. prausnitzii is lacking. Identifying dietary
microbiome modulators may help understanding how diet and phytochemicals can be employed in
medical nutrition therapy to increase the abundance of A. muciniphila and F. prausnitzii.
Therefore, the aim of this systematic review is to identify, integrate and discuss all available
evidence from clinical trials in humans on the association of diet with changes in A. muciniphila and
F. prausnitzii.
2. Material and Methods
2.1. Literature Search
This review was conducted and reported in accordance with the PRISMA [29] and MOOSE [30]
guidelines (Tables S1 and S2). PubMed and Embase were used to identify published studies from
database inception until April 23, 2019 (date last searched) that examined the associations between any
dietary factor and changes in A. muciniphila and F. prausnitzii in humans. To capture all relevant studies,
we used a broad search strategy using terms related to A. muciniphila and F. prausnitzii (Appendix A).
We did not apply any restrictions with regard to language and date. Furthermore, to identify additional
relevant studies, we checked the reference lists of the studies included in the current review.
2.2. Study Selection Criteria
To be included in the review, studies had to full-fill all of the following criteria: (i) were clinical
trials (randomized placebo-controlled trials, randomized trials comparing different exposures and
single-arm trials); (ii) included subjects 18+ years, and (iii) reported associations between any dietary
intervention and absolute and relative abundance of A. muciniphila, or F. prausnitzii, or both. As we
were interested to understand the effect of dietary factors on gut microbiome, we decided to include
all trials irrespective of their aim; therefore, all eligible trials that reported baseline and end of study
information on outcomes of interest were included in this review. Studies conducted in animals,
children/teenagers, conference abstracts, letters to the editor, interventions examining probiotics
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solely and non-interventional studies were excluded. Following the selection criteria, two reviewers
independently screened titles and abstracts for eligibility. Next, two reviewers assessed the full-text of
potentially eligible studies. In cases of disagreement, a decision was made by consensus or, if necessary,
a third reviewer was consulted.
2.3. Data Extraction
Two reviewers extracted the data independently using a predesigned form including study design,
study population, location, age range, dietary intervention and control (if applicable), duration of
intervention and study results.
2.4. Assessing the Quality of Trials
Two reviewers evaluated the risk of bias within each study using “The Cochrane Collaboration’s
tool” [31]. Studies were judged to be at low or high risk of bias based on criteria to evaluate
random sequence generation, allocation concealment, blinding of participants/personnel and outcome
assessment, incomplete outcome data and selective reporting. Trials were considered to be in low
risk of bias if allocation concealment, blinding of participants and outcome assessors were all coded
“yes”, if a compliance assessment was done and the number of dropouts and reasons for dropout were
reported; otherwise, the trials were considered to be at high risk of bias. If the risk of bias could not be
determined in any of the segments, (e.g., information not provided) the risk of bias was classified as
unknown. Lastly, for each trial, an overall score of quality was provided. Good quality was assigned
when all criteria were met (i.e. low risk of bias for each domain). Fair quality was assigned when
one criterion was not met (i.e. high risk of bias for one domain) or two criteria were unclear, and the
assessment that this was unlikely to have biased the outcome, and there is no known important
limitation that could invalidate the results. Poor quality was assigned when (i) one criterion was not
met or two criteria were unclear, and the assessment that this was likely to have biased the outcome,
and there are important limitations that could invalidate the results, or (ii) when two or more criteria
were listed as high or unclear risk of bias.
3. Results
3.1. Study Identification and Selection
In total, we identified 1433 relevant citations. After screening based on titles and abstracts,
59 citations were selected for detailed full text evaluation. Of those, 30 articles [23–28,32–55], based on
29 unique trials, met the selection criteria and were included in the review (Figure 1). Among these,
19 articles examined F. prausnitzii [26,27,32,34,36–39,41,42,44,46,47,49–52,54,55], five articles examined
A. muciniphila [23,28,35,43,48], and six articles examined both [24,25,33,40,45,53].
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3.2. Characteristics of the Included Trials
Of the 29 unique included trials, 15 were conducted in Europe, 8 in North America, 4 in Australia
and New Zealand, 1 in Iran, and 1 in China; 22 were conducted among both men and women, 4 among
men and 3 among women. Overall, the trials reported results for 1444 participants. All trials were
published after 2005 and 80 percent in the last 5 years. The baseline age of the participants was 18+.
The duration of the interventions ranged from 2 weeks to 6 months. The design of the included trials
comprised randomized double-blind placebo-controlled trials, single-arm trials, multi-arm parallel
trials, cross-over trials, and single and multi-centre trials. Detailed characteristics of the included trials
are presented in Tables 1 and 2. Two trials scored an overall good quality score, indicating a low risk of
bias in all domains (Table S3), whereas for the other trials the overall score was fair (n = 10) or poor
(n = 18). There was a low risk of bias for all trials in the domain sequence generation and allocation
concealment. For five trials, the risk of bias in the domain blinding of participants and personnel
was unclear. In the domain blinding of assessment, 16 trials had an unclear risk of bias, as this was
not clearly stated in these trials. Nine trials did not report how they handled missing data, and were
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therefore classified as being unclear in the assessment of risk of bias in the domain of missing data.
High risk of bias was found in the domain of selective reporting for 14 trials, as they did not report
effect estimates. The domain “other bias” included the risk of false positive findings for 14 trials,
as these trials did not account for multiple testing in their analysis.
3.3. Trials Examining A. muciniphila
Eleven trials examined the association between a dietary intervention and A. muciniphila [23–25,
28,33,35,40,43,45,48,53]. The dietary interventions examined were a caloric restriction diet, a reduced
energy diet, a diet low in fermentable oligo-, di-, mono-saccharides and polyols (FODMAP),
supplemental fibres, a yeast fermentate (EpiCor), sodium butyrare and inulin, pomegranate extract,
kiwifruit capsules, and resveratrol. Findings are summarized in Table 1.
Dao M et al. evaluated a caloric restriction diet compared to a weight stabilization diet among
overweight and obese participants [35]. In the caloric restricted group, the abundance of A. muciniphila
decreased in participants with a high baseline level of A. muciniphila and increased in participants
with low A. muciniphila levels. In the weight stabilization diet group, the abundance of A. muciniphila
decreased in participants with both low and high baseline levels of A. muciniphila. Similarly to
Dao M et al. [13], Medina-Vera I et al. examined a reduced energy diet compared to placebo in
patients with T2D [45]. They reported that consumption of the reduced-energy diet increased
levels of A. muciniphila by approximately 125%. However, two other studies coming from the same
cross-over trial examined a diet low in FODMAPs compared to a typical Australian diet containing
FODMAPs, and showed that the typical Australian diet increased absolute and relative abundance of
A. muciniphila [24,25].
A cross-over trial conducted showed that polydextrose supplementation increased A. muciniphila
compared to soluble corn fibre supplementation or placebo (i.e. no supplemental fibre control)
among healthy individuals [40]. Another cross-over trial reported no changes in relative or absolute
abundance of A. muciniphila after increasing the intake of resistant starch and wheat bran foods among
healthy individuals and patients with ulcerative colitis in remission [53]. Supplementation with
EpiCor, a yeast fermentate, increased A. muciniphila compared to placebo (maltodextrin) in healthy
individuals with moderate symptoms of gastrointestinal discomfort [48]. Supplementation with
sodium butyrate or inulin increased A. muciniphila compared to placebo (starch) in overweight and
obese diabetic patients, but no significant differences were found with combined sodium butyrate and
inulin supplementation [28].
Pomegranate extract increased A. muciniphila by 47-fold in healthy metabolite urolithin A producers
compared to non-producers [43]. However, kiwifruit capsules did not have a significant effect on
A. muciniphila abundance in healthy and functionally constipated individuals [33]. Resveratrol
supplementation led to an increase in A. muciniphila in USA Caucasians, but not in other ethnic
groups [23].
3.4. Trials Examining F. prausnitzii
Twenty-five studies examined the effect of dietary interventions on F. prausnitzii [24–27,32–
34,36–42,44–47,49–55]. Of these 25 studies, 17 studies examined prebiotics and the other studies
examined isoflavones, dietary fat, carbohydrates, a ketogenic diet, kiwifruit capsules, sun-dried raisins,
iron therapy, and a Chinese herbal formula. The findings are summarized in Table 2.
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Table 1. Descriptive Summary of Randomized Clinical Trials Investigating the Associations Between Dietary Interventions and Akkermansia Muciniphila.
Lead Author,
Publication Year
Study Design Location/Age
Range
Individual Health
Status
Total
Participants Sex
Period of
Intervention
Dietary Treatment Characteristics Main Findings
Intervention Type Control Type
Blatchford P
et al. 2017* [1]
Randomized
double-blind
placebo-controlled
cross-over trial
New Zealand/
23–56
Healthy participants
with no clinical
symptoms of
constipation and
functionally
constipated
participants
29 W and M
4 weeks each
intervention (2 weeks
washout period
between each
intervention)
ACTAZIN™ (600 mg/d)
green kiwifruit extract
low dose
Placebo (isomalt
coloured green
2400 mg/d)
A. muciniphila was significantly more
abundant in the functionally
constipated group, but no effect of the
interventions on A. muciniphila.
ACTAZIN™
(2400 mg/d) green
kiwifruit extract high
dose
Livaux™ (2400 mg/d)
gold kiwifruit extract
Dao M
et al. 2015 [13]
Single-arm
cross-over trial
France/
41.9 ± 12.3
Overweight and
obese participants 49 W and M 12 weeks
Caloric restriction diet
(1200 kcal/d for W and
1500 kcal/d for M)
Weight stabilization
diet (prescribed
individually by a
dietitian)
Caloric restriction diet: Subjects with
A. muciniphila at or above the median
had a decrease in abundance of A.
muciniphila while in the group with A.
muciniphila lower than median there
was an increase. The difference was
statistical significant.
Weight stabilization diet: In both
subjects with A. muciniphila at or
above and lower, there was a decrease
in abundance of A. muciniphila with no
difference between the groups.
Halmos EP
et al. 2015* [16]
Single-arm blinded
randomized
cross-over trial
Australia/18+
Healthy participants
and participants with
irritable bowel
syndrome
33 W and M 6 weeks Diet low in FODMAPs
Diet containing
FODMAP content of a
typical Australian diet
Typical Australian diet increased
absolute and relative abundance for
mucus-associated A. muciniphila
(p < 0.001).
Halmos EP et al.
2016* [17]
Single-arm blinded
randomized
cross-over trial
Australia/18+
Patients with
clinically quiescent
Crohn’s disease
9 W and M 6 weeks Diet low in FODMAPs
Diet containing
FODMAP content of a
typical Australian diet
Relative abundance was higher for
mucus-associated A. muciniphila
during the Australian compared with
low FODMAP diet (p = 0.016).
Hooda S et al.
2012* [6]
Randomized
double-blind
placebo-controlled
cross-over trial
USA/
27.5 ± 4.33 Healthy participants 25 M 9 weeks
Polydextrose (PDX)
(7 g, 3 times per day)
Placebo (no
supplemental fiber
control (NFC) (0 g,
3 times per day))
A. muciniphila was greater after PDX
intake than after the NFC or SCF
treatment (p < 0.05).Soluble corn fiber (SCF)
(7 g, 3 times per day)
James SL et al.
2015* [54]
Randomized
single-blind
cross-over trial
Australia/
18–72
Patients with UC in
remission and healthy
subjects
29 W and M 8 weeks
‘Low resistant starch
(RS)/wheat bran (WB)’
foods containing 2–5 g
RS and
2–5 g WB fibre per day
NA
Patients with UC had a lower
abundance of A. muciniphila. For both
cohorts, increasing the intake of
RS/WB gave no indication of changes
in relative or absolute abundance.
‘High RS/WB’ foods
containing 15 g
RS and 12 g WB fibre
per day
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Table 1. Cont.
Lead Author,
Publication Year
Study Design Location/Age
Range
Individual Health
Status
Total
Participants Sex
Period of
Intervention
Dietary Treatment Characteristics Main Findings
Intervention Type Control Type
Li Z
et al. 2015 [20] Single-arm trial USA/28.9 ± 8 Healthy volunteers 20 W and M 4 weeks
Pomegranate extract
(1000 mg) NA
The data were not shown for the
overall population. A. muciniphila was
33 (at baseline) and 47 fold (after
4 weeks) higher in stool samples of
Urolithin A producers compared to
non-producers.
Medina-Vera I
et al. 2019* [9]
Randomized,
double-blind
placebo-controlled
trial
Mexico/30–60 Patients with Type 2Diabetes 81 W and M 3 months
A reduced-energy diet
with a dietary portfolio
(DP) (14 g of
dehydrated nopal, 4 g
of chia seeds, 30 g of
soy protein and 4 g of
inulin)
Placebo (28 g of calcium
caseinate and 15 g of
maltodextrin)
DP consumption increased levels of
A. muciniphila by approximately 125%.
Pinheiro I
et al. 2017 [11]
Randomized,
double-blind
placebo-controlled
trial
Belgium/20–69
Healthy with reduced
bowel movements
and other symptoms
of GI discomfort
stratified in severe
and moderate
80 W and M 6 weeks EpiCor fermentate(500 mg/d)
Placebo (maltodextrin
(500 mg/d))
Significant relative increase of A.
muciniphila in the moderate GI
discomfort symptoms group at visit
week 3 (p = 0.0001) and visit week 6
(p = 0.036).
Roshanravan N
et al. 2017 [25]
Randomized,
double-blind
placebo-controlled
trial
Iran/30–55
Overweight and
obese diabetes
patients
60 W and M 6 weeks
Group A: Butyrate
group (600 mg/d
sodium butyrate +
inulin placebo)
Butyrate + inulin
placebo (6
starch capsules
(100 mg) and 10 g of
starch powder)
The percentage changes of A.
muciniphila abundance indicated a
significant increase in group taking
sodium butyrate and inulin (group A
and B) in comparison with the placebo
group (p < 0.05). A non-significant rise
in this bacterium concentration was
seen after supplementation with both
sodium butyrate and inulin (group C).
Group B: inulin group
(10 g/d inulin powder +
butyrate placebo)
Group C: butyrate +
inulin group (600 mg/d
sodium butyrate +
10 g/d inulin powder)
Walker JM et al.
2019 [27]
Randomized,
double-blind
placebo-controlled
trial
USA/30–70
Obese insulin
resistant subjects with
metabolic syndrome
28a M 5 weeks
Resveratrol (500 mg
Mega-RES 99%
capsules twice daily)
Placebo (two 500 mg
placebo capsules twice
daily)
Overall, there was no difference.
However, when split by ethnicity,
resveratrol administration to
Caucasian subjects led to an increase
in A. muciniphila compared to the
non-Caucasians.
* Studies examining both A. Muciniphila and F. Prausnitzii. FODMAPs Fermentable Oligosaccharides, Disaccharides, Monosaccharides and Polyols; FOS fructo-oligosaccharides;
GI gastrointestinal; M men; NA not applicable; UC ulcerative colitis; W women. a Stool samples collected in 16 subjects.
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Table 2. Descriptive Summary of Randomized Clinical Trials Investigating the Associations Between Dietary Interventions and Faecalibacterium prausnitzii.
Lead Author,
Publication Year
Study Design Location/Age
Range
Individual Health
Status
Total
Participants Sex
Period of
Intervention
Dietary Treatment Characteristics
Main Findings
Intervention Type Control Type
Benjamin JL et al.
2011 [12]
Randomized
double-blinded
placebo-controlled
trial
UK/39.5 ± 14.4 Patients with Crohn’sdisease 103 M 4 weeks
Normal diet
supplemented with
15 g/day FOS,
comprising fructose
polymers of differing
chain lengths
Placebo (maltodextrin
15 g/day)
No significant differences between
patients in the FOS and placebo group at
week 4 (p = 0.95).
Benus RFJ et al.
2010 [52]
Randomized
double-blinded
cross-over trial
UK/21–34 Healthy 14 W and M 4 weeks
A formula
supplemented
with dietary fibre
(14 g/l) consisting of
pea fibre and
fructo-oligosaccharides
NA
There were large and statistically
significant reductions in the numbers of
the F. prausnitzii group during both the
fibre-free and fibre-supplemented diets.
No differences between the fibre-free
and fibre-supplemented diet (p = 0.23).
A fibre-free enteral
formula
Blatchford P et al.
2017* [1]
Randomized
double-blind
placebo-controlled
cross-over trial
New
Zealand/23–56
Healthy participants who
had no clinical symptoms
of constipation and
functionally constipated
participants
29/W and M W and M
4 weeks each
intervention (2 weeks
washout period
between each
intervention)
ACTAZIN™ L
(600 mg/d)
Placebo (isomalt
coloured green
2400 mg/d)
F. prausnitzii abundance significantly
increased from 3.4 to 7.0% following
Livaux™ supplementation in the
functionally constipated group
(p = 0.024).
ACTAZIN™ H
(2400 mg/d)
Livaux™ (2400 mg/d)
Clavel T et al.
2005 [2]
Randomized
double-blind
placebo-controlled
trial
France/
60.4 ± 7.1 Postmenopausal women 39 W 30 days
Probiotic group:
isoflavones
(100 mg/d) + B.
animalis DN-173 010
Placebo (isoflavones
100 mg/d)
Bacterial percentages for F. prausnitzii
subgroup decreased significantly in
control subjects compared to the
probiotic and prebiotic group (p = 0.034).Prebiotic group:
isoflavones (100
mg/d) + FOS (7 g/d)
Dewulf EM et al.
2012 [3]
Double-blind
placebo-controlled
trial
Belgium/
47.5 ± 8.5 Obese 30 W 3 months
ITF prebiotics
(Synergy 1, namely,
inulin/oligofructose
50/50 mix)
Placebo (maltodextrin)
Treatment with ITF prebiotics, but not
the placebo, led to an increase in
F. prausnitzii.
Fava F et al.
2013 [14]
Five-arm parallel,
placebo-controlled,
single-blind study
UK/56.0 ± 9.5
Individuals at increased
risk of metabolic
syndrome
88 W and M 24 weeks
High SFA diet
NA
Numbers of F. prausnitzii increased after
intervention with high CHO and low GI
(p = 0.022) and high SFA (p = 0.018) diet
compared to baseline.
High MUFA/high GI
High MUFA/Low GI
High CHO/High GI
High CHO/Low GI
Fernando WMU
et al. 2010 [4]
Randomized
cross-over trial
Canada/
25.6 ± 8.7 Healthy 12 W and M 9 weeks
Control diet + 5 g/d
raffinose Control diet
F. prausnitzii was more abundant in the
raffinose diet and the chickpea diet
compared to the control diet.Control diet + 200 g/d
canned chickpea
Guadamuro L
et al. 2015 [15] Single-arm trial Spain/48–61
Menopausal women with
no chronic disease 16 W 24 weeks
One tablet
isoflavoneconcentrate
(80 mg) per day
NA There was an increase in the intensity ofF. prausnitzii.
Halmos EP et al.
2015* [16]
Single-arm blinded
randomized
cross-over trial
Australia/18+ Irritable bowel syndromeand healthy individuals 33 W and M 6 weeks
Diet low in
FODMAPs
Diet containing
FODMAP content of a
typical Australian diet
Low FODMAP diet reduced total
bacterial abundance, but did not impact
relative abundance of F. prausnitzii.
Halmos EP et al.
2016* [17]
Single-arm blinded
randomized
cross-over trial
Australia/18+ Patients with clinicallyquiescent Crohn’s disease 9 W and M 6 weeks
Diet low in
FODMAPs
Diet containing
FODMAP content of a
typical Australian diet
No significant difference in F. prausnitzii
between the two diets.
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Table 2. Cont.
Lead Author,
Publication Year
Study Design Location/Age
Range
Individual Health
Status
Total
Participants Sex
Period of
Intervention
Dietary Treatment Characteristics
Main Findings
Intervention Type Control Type
Hooda S et al.
2012* [6]
Randomized
double-blind
placebo-controlled
cross-over trial
USA/
27.5 ± 4.33 Healthy 25 M 9 weeks
Polydextrose (PDX)
(7 g, 3 times per day)
Placebo: no
supplemental fiber
control (NFC) (0 g,
3 times per day)
F. prausnitzii was greater in participants
when they consumed PDX or SCF than
when they consumed NFC (p < 0.05).Soluble corn fiber
(SCF) (7 g, 3 times per
day)
Hustoft TN et al.
2016 [7]
Randomized
double-blind
placebo-controlled
cross-over trial
Norway/18–52
Diarrhea-predominant or
mixed irritated bowel
syndrome
20 W and M
10 days each
intervention (3 weeks
washout period)
Fructo-oligosaccharides
(FOS) 16 g/d
Placebo: Maltodextrin
16 g/d
Ten days of FOS supplementation
increased the level of F. prausnitzii.
James SL et al.
2015* [54]
Randomized
single-blind
cross-over trial
Australia/18–72
Patients with UC in
remission and healthy
subjects
29 W and M 8 weeks
‘Low resistant starch
(RS)/wheat bran (WB)’
foods containing
2–5 g RS and
2–5 g WB fibre per
day
NA
For both cohorts, increasing the intake
of RS/WB gave no indication of changes
in relative or absolute abundance in F.
prausnitzii.
‘High RS/WB’ foods
containing 15 g
RS and 12 g WB fibre
per day
Lee T et al.
2017 [19]
Randomized,
double-blind
placebo-controlled
trial
Canada/18+
Iron deficient
Inflammatory bowel
disease patients
72 W and M 12 weeks
Oral iron sulfate
300 mg, tablet, twice a
day
Iron sucrose, 300 mg,
intravenous, three or
four/day
Lower abundance of F. prausnitzii after
oral iron therapy compared to
intravenous iron therapy (p = 0.009).
Majid HA et al.
2014 [8]
Multi-centre,
randomized
double-blind
controlled trial
UK/70.8 ± 9.7
Patients from the ICU
starting exclusive
nasogastric enteral
nutrition
22 W and M Up to 14 days Oligofructose/inulin7 g/d
Placebo: maltodextrin
7 g/d
There were significantly lower
concentrations of F. prausnitzii in
patients receiving additional
oligofructose/inulin (p = 0.01).
Medina-Vera I
et al. 2019* [9]
Single-centre
randomized,
controlled,
double-blind
parallel-group trial
Mexico/30–60 Patients with Type 2Diabetes 81 W and M 3 months
A reduced-energy
diet with a dietary
portfolio (DP)
comprising 14 g of
dehydrated nopal, 4 g
of chia seeds, 30 g of
soy protein and 4 g of
inulin
Placebo, comprising of
28 g of calcium
caseinate and 15 g of
maltodextrin.
Dietary intervention with functional
foods significantly modified faecal
microbiota compared with placebo. DP
consumption for 12 weeks increased
levels of F. prausnitzii by approximately
34%.
Moreno-Indias I
et al. 2016 [21]
Randomized,
cross-over
controlled trial
Spain/45–50 Metabolic syndrome andhealthy individuals 20 M 10 weeks (75 days)
Red wine, 272
mL/day
De-alcoholized (no
ethanol) red wine,
272 mL/dat
In metabolic syndrome patients, there
was a significant increase of F.
prausnitzii, after the red wine and
de-alcoholized red wine intake periods
compared to baseline. In the healthy
group, a significant increase in the
number of F. prausnitzii through the
intervention period was observed.
Most J et al.
2017 [10]
Randomized
double-blind
placebo-controlled
trial
The
Netherlands/
20–50
Obese 42 W and M 12 weeks
A combination of
epigallocatechin-3-gallate
(EGCG) and
resveratrol (RES)
supplements (EGCG
+ RES; 282 and 80
mg/day, respectively)
Placebo (partly
hydrolyzed
microcrystalline
cellulose-filled
supplements)
EGCG+RES supplementation
significantly decreased Bacteroidetes
and tended to reduce F. prausnitzii in
men (p = 0.05 and p = 0.10, respectively)
but not in women (P = 0.15 and P = 0.77,
respectively).
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Table 2. Cont.
Lead Author,
Publication Year
Study Design Location/Age
Range
Individual Health
Status
Total
Participants Sex
Period of
Intervention
Dietary Treatment Characteristics
Main Findings
Intervention Type Control Type
Ramirez-Farias C
et al. 2008 [23]
Randomized,
cross-over trial UK/38.1 ± 2.43 Healthy adults 12 W and M 3 weeks
Inulin–oligofructose,
5 g, twice daily
Did not consume any
supplement
F. prausnitzii exhibited a significant
increase after intervention (p = 0.019).
Ramnani P et al.
2010 [24]
Three-arm parallel,
placebo-controlled,
double-blind study
UK/18–50 Healthy adults 60 W and M
3 weeks intervention
(3 weeks washout
period)
Jerusalem artichoke
(JA) inulin-
predominantly made
of pear-carrot-sea
buckthorn and JA
juices or purées (PCS);
two 100 mL shots per
day
Placebo: Water-based
preparation with added
sugar, thickened and
flavoured with blood
orange, carrot and
raspberry extracts and
flavours (but no juice or
purees)
No significant differences during the
intervention and washout period.
JA inulin-
predominantly made
of plum-pear-beetroot
and JA juices or
purées (PPB); Two
100 mL shots per day
Tagliabue A et al.
2017 [26] Single-arm trial USA/18–34
Glucose Transporter 1
Deficiency Disorder
(GLUT1-DS) patients
6 W and M 12 weeks
Ketogenic diet
including a minimum
of 0.8–1 gram per
kilogram of body
weight of protein
from animal sources
(e.g., eggs, milk, meat,
poultry and fish)
NA There was no statistical significantdifference.
Vulevic J et al.
2013 [55]
Randomized
double-blind
placebo-controlled
cross-over trial
UK/45.2 ± 11.9
Overweight subjects
predisposed to the
development of
metabolic syndrome
45 W and M
12 weeks each
intervention (4 week
washout period)
Bi2muno (B-GOS) Placebo (maltodextrin)
The two dietary interventions had no
significant effects on counts of total
bacteria and F. prausnitzii cluster during
the study.
West NP et al.
2013 [56]
Randomized
double-blind
controlled trial
Australia/
37.4 ± 8.4 Healthy active cyclists 41 W and M 28 days
Ingestion of 40 g/day
of butyrylated high
amylose maize starch
(HAMSB)
Low amylose maize
starch (LAMS)
There were relative greater increases in
faecal F. prausnitzii (5.1-fold; p < 0.01) in
the HAMSB group.
Wijayabahu AT
et al. 2019 [28] Single-arm trial USA/18–59 Healthy individuals 13 W and M 2 weeks
Sun-dried raisins:
Three servings per
day; one serving
contained 28.3 g
raisins and 2 grams of
dietary fiber
NA
F. prausnitzii significantly
increased after the first week of raisin
intake and this increase continued
during the second week of raisin
consumption (p < 0.05).
Xu J et al.
2015 [29]
Randomized,
double-blind
placebo-controlled
clinical trial
China/
8.5 ± 2.6
Recently diagnosed
type-2 diabetes patients 187 W and M 12 weeks
Low dose of Gegen
Qinlian Decoction
Placebo
All three doses of GQD treatment
significantly enriched F. prausnitzii
compared with baseline.Medium dose of
Gegen Qinlian
Decoction
High dose of Gegen
Qinlian Decoction
* Studies examining both A. Muciniphila and F. Prausnitzii. CHO Carbohydrate; GI Glycemic index; FODMAPs Fermentable Oligosaccharides, Disaccharides, Monosaccharides and
Polyols; FOS fructo-oligosaccharides; ICU intensive care unit; ITF Inulin-type fructans; M men; MUFA monosaturated fat; SFA Saturated fatty acids; UC ulcerative colitis; W women.
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Treatment with prebiotic inulin-type fructans led to an increase of F. prausnitzii compared to placebo
(maltodextrin) in obese women [36]. Supplementation of fructo-oligosaccharides, which are prebiotic
fructans, increased the level of F. prausnitzii compared to placebo (maltodextrin) in patients with
diarrhoea or mixed irritated bowel syndrome [41]. Supplementation of prebiotic inulin-oligofructose
also increased the level of F. prausnitzii in healthy individuals [26]. Moreno-Indias I. et al. studied
the prebiotic effect of red wine in male metabolic syndrome patients and healthy individuals and
reported an increase of F. prausnitzii for red wine intake compared to baseline [46]. Another study
found that F. prausnitzii was greater when healthy men consumed polydextrose or soluble corn fiber
supplementation, which could be potential prebiotics, than when they consumed no supplemental
fiber [40]. Medina-Vera I. et al. examined the effect of a reduced energy diet with prebiotic properties
compared to a placebo diet in patients with type 2 diabetes, and reported an increase of F. prausnitzii of
34% [45]. Fernando WMU et al. studied the prebiotic potential of chickpea oligosaccharides (raffinose)
alone or as components of chickpea and found that F. prausnitzii was more abundant in the raffinose
diet and the chickpea diet compared to the control diet [38]. Ingestion of butyrylated high amylose
maize starch led to greater relative increases of F. prausnitzii compared to ingestion of low amylose
maize starch [55].
However, there are also studies reporting a decrease in F. prausnitzii after a prebiotic intervention.
Patients from the intensive care unit starting nasogastric enteral nutrition receiving additional
oligofructose/inulin had significantly lower concentration of F. prausnitzii compared to patients receiving
placebo [44]. A combination of epigallocatechin-3-gallate and resveratrol decreased F. prausnitzii
compared to placebo in obese men but not in obese women [47]. A cross-over trial comparing a
fibre-free enteral formula or a formula supplemented with dietary fibre consisting of pea fibre and
fructo-oligosaccharides showed large reductions in the number of F. prausnitzii during both the fibre-free
and fibre-supplemented diets among healthy participants [52].
Moreover, some studies reported no differences in F. prausnitzii after a prebiotic intervention.
Halmos E. et al. examined a diet low in FODMAPs compared to a diet containing FODMAPs in
two different studies in patients with irritated bowel syndrome and patients with clinically quiescent
Crohn’s disease [24,25]. They did not report significant differences in F. prausnitzii between the diets
in both studies. Another study conducted among men with Crohn’s disease examining the effect of
fructo-oligosaccharides compared to a non-prebiotic carbohydrate also did not found differences in
F. prausnitzii [32]. Vulevic J. et al. investigated the effect of administering Bi2muno (B-GOS) compared to
placebo (maltodextrin) in a cross-over trial among overweight subjects predisposed to the development
of metabolic syndrome, and reported no significant effects on counts of the F. prausnitzii cluster during
the study [54]. Increasing the intake of resistant starch and wheat bran foods containing fibres did
not change the relative and absolute abundance of F. prausnitzii in healthy participants and patients
with ulcerative colitis in remission [53]. Among healthy individuals, Ramnani P. et al. studied the
prebiotic effect of Jerusalem artichoke compared to a placebo, but did not report significant differences
in F. prausnitzii [27].
Clavel T. et al. studied the effect of a prebiotic (isoflavones and fructo-oligosaccharides) or probiotic
(isoflavones and B. animalis DN-173 010) compared to placebo (isoflavones alone) in postmenopausal
women [34]. They reported that percentages of F. prausnitzii decreased significantly in control subjects
compared to probiotic and prebiotic groups. Guadamuro L. et al. examined the effect of isoflavone
concentrate supplementation alone in menopausal women and found an increase in the intensity of
F. prausnitzii after isoflavone supplementation [39].
Fava F. et al. showed that the type and quantity of dietary fat and carbohydrate can alter faecal
microbiome in individuals at increased risk of metabolic syndrome, whereby F. prausnitzii increased
after intervention of a diet with high monounsaturated fatty acids and a high glycaemic index,
compared to diets with high saturated fatty acids, high monounsaturated fatty acids in combination
with a low glycaemic index, or with high carbohydrates in combination with high or low glycaemic
index [37]. A ketogenic diet including a minimum of 0.8-1 gram per kilogram of bodyweight of
Nutrients 2019, 11, 1565 12 of 20
protein from animal sources did not have an effect on F. prausnitzii [49]. Consumption of kiwifruit
capsules increased F. prausnitzii abundance in functionally constipated individuals, compared to
placebo [33]. Addition of sun-dried raisins to the diet also increased the abundance of F. prausnitzii
among healthy individuals [50]. Oral iron therapy resulted in lower abundance of F. prausnitzii
compared to intravenous iron therapy among iron deficient inflammatory bowel disease patients [42].
Xu J et al. examined the effect of a Chinese herbal formula (Gegen Qinlian Decoction) in a low, medium
and high dose in recently diagnosed type 2 diabetes patients. They reported that all three doses of
Gegen Qinlian Decoction treatment significantly enriched F. prausnitzii compared with baseline [51].
4. Discussion
In the current systematic review of clinical trials, diet-induced changes in A. muciniphila and
F. prausnitzii were reviewed. An increase in abundance of A. muciniphila was observed after a
caloric restriction diet, supplementation with pomegranate extract, resveratrol, polydextrose, EpiCor
or sodium butyrate, whereas a diet low in FODMAPs decreased the abundance of A. muciniphila.
Prebiotics use was the main dietary intervention investigated in relation to F. prausnitzii, showing
contradictory results depending on the type of prebiotics. Isoflavone supplementation and intake
of some types of fatty acids, such as monounsaturated fatty acids, was associated with increased
abundance of F. prausnitzii, whereas inulin intake and a reduced energy diet increased the abundance
of both A. muciniphila and F. prausnitzii.
Approximately 100 trillion microorganisms are present in the body but mostly residing in the
gastrointestinal tract [56]. In response to environmental changes, the gut microbiome can affect gene
expression in humans. While around 23,000 genes make up the human genome, the microbiome
consists over 3 million genes producing thousands of metabolites, and therefore affecting many aspects
of human health, including gastrointestinal and cardiometabolic phenotypes [56,57]. Changes in
microbiota are observed in patients with inflammatory gastrointestinal disease, prediabetes, and T2D,
particularly a decreased abundance of A. muciniphila and F. prausnitzii [58]. In addition, low abundance
of A. muciniphila and F. prausnitzii has been associated with increased inflammatory processes and
atherosclerosis, and F. prausnitzii transplantation has been shown to be an effective therapeutic
approach for diabetes and its complications [59]. F. prausnitzii is an important butyrate-producer
with anti-inflammatory properties, while A. muciniphila degrades mucin in the gut lining resulting in
syntrophic interactions and stimulation of intestinal metabolite pool [60]. For example, co-cultivations
of A. muciniphila with butyrate-producing bacteria resulted in syntrophic growth and butyrate
production [60]. Butyrate plays an important role in anti-inflammation and maintaining intestinal barrier
integrity by modulating intestinal macrophages’ function, downregulating lipopolysaccharide-induced
pro-inflammatory mediators, such as nitric oxide, IL-6, and IL-12, inducing the differentiation of
regulatory T cells and stabilizing hypoxia-inducible factor [61–64]. Further, butyrate can have beneficial
effects on glucose and energy homeostasis by activating intestinal gluconeogenesis, as well as inducing
apoptosis of colon cancer cells [65]. Studies in animal models have shown that colonization by
A. muciniphila resulted in transcriptional changes, leading to an increase in the expression of genes
associated with immune responses and cellular lipid metabolism [11,66]. Besides degrading mucins,
A. muciniphila can also stimulate mucin production, suggesting an autocatalytic process [67,68]. Mucins
are large, highly glycosylated proteins that play a crucial role in luminal protection of the gastrointestinal
tract, thereby reducing translocation of pro-inflammatory lipopolysaccharides, controlling fat storage,
adipose tissue metabolism, and glucose homeostasis [68,69]. Therefore, altering the abundance and
dynamics of these two strains of bacteria can lead to alterations in metabolic processes, and prevention
and management of metabolic diseases.
Diet is the main source of energy to humans, but can also modulate microbiota and impact
host-microbe interactions [70]. Therefore, gut microbiota may be crucial in mediating the health
effects of foods. The gut microbiota provides the exoenzymes to catalyze and ferment substrates that
cannot be completely digested by the human digestive tract to produce metabolites such as short
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fatty acids including butyrate [71]. Such non-digestible substrates include complex carbohydrates
derived from plants and dietary fibres from cereals, legumes, vegetables, fruits, and nuts. Modulation
of the gut microbiome through adherence to a high-fibre plant-based diet has been suggested as a
potential therapeutic approach for prevention and treatment of inflammatory gastrointestinal diseases
and metabolic diseases such as T2D and restoration of microbiota function [72,73]. In line with
this hypothesis, we found in the current review that inulin-type fructans, fructo-oligosaccharides,
polydextrose or soluble corn fiber supplementation, and raffinose can lead to increase abundance of
A. muciniphila and/or F. prausnitzii. However, we found no consistent associations or decreases for other
types of prebiotics and abundance of F. prausnitzii such as inulin-oligofructose and resistant starch or
wheat bran foods. Yet, this inconsistency is somehow expected considering that studies used different
types of prebiotics, for which bacteria have differing specificity and therefore affecting differently the
number of fermentable substrates in the gut [14]. In addition, different types of fibres have differing
effects in the luminal pH and transit rate. Type of fibre being consumed, gut transit time, and the
functional capabilities of gut microbiota influences the fermentation of carbohydrate and subsequent
regional delivery of metabolites [14]. Hence, the different results we see in this study on the association
between prebiotics and F. prausnitzii may reflect this complexity. This is also in line with the findings
from observational studies showing that some types of dietary fibres (such as those from cereals) but
not all are associated with reduced risk of T2D [74].
Pomegranate extract, a rich and varied source of polyphenolic compounds, and resveratrol
polyphenol have been widely investigated for their antioxidant, anti-inflammatory, anti-diabetic and
anti-atherogenic properties in both genders [75,76]. Phytoestrogens seem to have similar effects but
mainly in women; use of phytoestrogens in women is associated with improvement of menopausal
symptoms, better glycaemic control and reduced risk of T2D [77,78]. However, the mechanisms of
action of these compounds remain unclear. Microbiome plays an important role in metabolizing the
non-absorbed fraction of these compounds, and therefore defining the ability of these compounds such
as polyphenols to exert health effects [79]. On the other hand, pomegranate and polyphenol resveratrol
can modulate the abundance of A. muciniphila, while isoflavone phytoestrogens alone, and not in
combination with fibres, can modulate the abundance of F. prausnitzii [19,23,34,39,43]. While it is not
completely clear how such compounds can affect intestinal microorganisms, limited evidence suggests
that it could be either by the selective pressure they exert on specific microorganisms, or by modifying
environmental conditions of the intestinal tract [34].
Modifying the diet can lead to rapid changes in microbiota within the first days. A study
reported human gut microbiome changes after only 24 hours after shifting between plant and
animal protein-based diets [80]. Similarly, the studies included in this review showed that dietary
interventions are associated with changes in A. muciniphila and F. prausnitzii in the first weeks of
intervention [26,41,44,50]. This suggests that diet may be an important and fast modifier of A. muciniphila
and F. prausnitzii, and the microbiome in general, and a promising future therapeutic approach to
prevent and treat inflammatory and metabolic conditions associated with specific microbiome strains.
Our study highlights several additional factors that might be important to consider for a more
comprehensive understanding of diet-related diseases and to elucidate the links between nutrition and
dynamics of A. muciniphila and F. prausnitzii. However, dietary effects on microbiome may depend
on health status, the baseline abundance of bacteria strains already in the gut, ethnicity, medication,
and sex [24,25,32–35,37,41,42,45,46,51]. This could also explain the inconsistent results across studies
in this systematic review, as we included studies among different sexes, ethnicities and health statuses.
For instance, men and women have different genetic background, energy and nutritional requirements
across the lifespan, as well as differences in gastrointestinal transit time, which can contribute to sex
differences in microbiome [81,82]. Therefore, considering the sex-differences in the gut microbiome
can provide novel insights in tailoring interventions and treatment, and therefore improving precision
medicine. Machine-learning algorithms can help to predict inflammatory metabolic responses to meals,
microbiome and how that differs by sex and ethnicity, and thus help to improve the emerging concept
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of personalized nutrition. For example, Zeevi et al. [83] used a machine-learning algorithm to predict
personalised glucose responses after meals based on clinical and gut microbiome data. Based on the
algorithm, a dietary intervention was designed and successfully shown to normalize blood glucose
levels in a double-blinded randomised crossover trial of 26 patients [83]. Future research based on
a large population-based studies and clinical trials is needed to evaluate a greater variety of food
components and establish whether such personalised nutritional approaches based on microbiome
composition are feasible and can improve clinical outcomes.
Further, it may be important to understand the differences that whole foods and ultra-processed
foods may have on gut microbiota and subsequently on health outcomes. It has been shown that
fibre-rich ultra-processed foods change the microbiota towards a less diverse and less beneficial
composition compared to fibre-rich whole foods [84]. Processed foods have been undergone high
heat and pressure, which can lead to several chemical and physical changes, including inactivation of
endogenous enzymes, increased content of soluble dietary fibre and mechanical damage to the cell
walls [85]. This suggests that whole unprocessed foods will enter the colon in an intact state which
could favour the growth of bacteria that degrade fibre and produce beneficial metabolites, and thus
exerting protective effects on health outcomes [85]. This theory is also supported from epidemiological
studies showing that whole foods such as whole fish and whole grains can have a more beneficial
effect than processed fish and refined grains, and that processed meat is in general associated with
a stronger adverse health effect than whole meat [86]. Therefore, investigating the health effects of
nutrients present in ultra-processed and whole food in the context of the microbiome can shed light on
the mechanisms of the adverse effects of the Western diet.
To our knowledge, this is the first systematic review on the subject that critically and systematically
appraised the literature on the effect of dietary interventions on A. muciniphila and F. prausnitzii.
Nevertheless, some limitations from the included studies in this review merit careful consideration.
Firstly, not all studies reported baseline and/or end of trial estimates between groups, and therefore
the interpretation and the strength of the reported associations remained unclear. This and other
factors (such as different types of study populations, interventions, and study designs) also limited
providing a meaningful quantitative pooling of the existing data. It is important that future studies
report summary estimates for all bacteria strains under investigation, and not apply selective reporting.
Further, the studies included in this review were of suboptimal quality and the conclusions should be
interpreted with caution. Most studies have been published in recent years and were conducted in
limited sample sizes (16 studies had ≤30 participants) within interventions lasting short time periods
(15 studies lasted for ≤6 weeks). Moreover, we cannot exclude the possibility that the changes we
observed in A. muciniphila and F. prausnitzii are due to changes that dietary factors can lead to in the
health condition of the participants, rather than the effect of diet alone. Nevertheless, most of clinical
trials included in this review were performed in healthy individuals, and therefore we would expect
that it is less likely that dietary factors we examined alter the abundances of the bacteria strains through
changes in health. We also cannot exclude the possibility that the dietary factors lead to changes in
other bacterial strains, which might have an effect on A. muciniphila and F. prausnitzii. What appears to
be a promising field for intervention to improve health is also highly complex and new studies are
required to untangle these complex interactions of diet, microbiome, and diseases in larger populations.
5. Conclusions
In summary, we found that specific dietary interventions could influence the abundance of
A. muciniphila and F. prausnitzii, highlighting a novel potential mechanism describing how diet can
affect inflammatory and metabolic health outcomes. Understanding the links between different types
of dietary interventions and changes in abundance of A. muciniphila and F. prausnitzii can help shaping
future nutritional recommendations and designing medical nutrition therapies that can help prevent
and treat diseases related to these two strains of bacteria such as inflammatory gastrointestinal disease
and T2D.
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Appendix A
Search Strategy
PUBMED 384
(akkermansia[All Fields] AND muciniphila[All Fields]) OR (“faecalibacterium prausnitzii”[MeSH
Terms] OR (“faecalibacterium”[All Fields] AND “prausnitzii”[All Fields]) OR “faecalibacterium
prausnitzii”[All Fields]) AND “humans”[MeSH Terms].
EMBASE 1049
((‘akkermansia muciniphila*’: ab, ti OR ‘faecalibacterium prausnitzii*’: ab, ti) OR (‘akkermansia
muciniphila’/exp OR ‘faecalibacterium prausnitzii’/exp)) AND ‘human’/de.
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